ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
top-line data due in Q2 and a potential supplemental BLA filing ~4–5 months after the readout that could lead to approval around mid-2027 if positive. Early combination data from Phase Ib LOTIS-7 (ZYNLONTA + glofitamab) showed a 90% overall response rate and 78% complete response rate in 49 evaluable patients, with reduced cytokine release syndrome (~25% all-grade at the approved dose) and 100-patient data expected by year-end. Commercially, third-line ZYNLONTA sales have been variable but roughly stable (Q4 $22.3M); management says second-line approval could expand the addressable population by ~12,000 patients and drive revenue toward the $200–$300M range, while $261M in cash should fund operations into 2028. Interested in ADC Therapeutics SA? Here are five stocks we like better. ADC Therapeutics (NYSE:ADCT) executives used a recent fireside chat at the H.C. Wainwright conference to outline the company's strategy to expand the reach of its CD19-directed antibody-drug conjuga
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript [Seeking Alpha]Seeking Alpha
- ADC Therapeutics (ADCT) had its price target raised by HC Wainwright from $7.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 3/10/26 - Beat
ADCT
Sec Filings
- 3/17/26 - Form EFFECT
- 3/16/26 - Form 424B3
- 3/10/26 - Form S-3
- ADCT's page on the SEC website